Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Iasonas Kapralos"'
Publikováno v:
Pharmaceutics, Vol 13, Iss 10, p 1578 (2021)
The aim of the study is to develop a population pharmacokinetic (PPK) model, of Octreotide long acting repeatable (LAR) formulation in healthy volunteers, which describes the highly variable, multiple peak absorption pattern of the pharmacokinetics o
Externí odkaz:
https://doaj.org/article/5dfb8dfa670c40be9f46d742b21e5558
Publikováno v:
Pharmaceutics
Volume 13
Issue 10
Pharmaceutics, Vol 13, Iss 1578, p 1578 (2021)
Volume 13
Issue 10
Pharmaceutics, Vol 13, Iss 1578, p 1578 (2021)
The aim of the study is to develop a population pharmacokinetic (PPK) model, of Octreotide long acting repeatable (LAR) formulation in healthy volunteers, which describes the highly variable, multiple peak absorption pattern of the pharmacokinetics o
Autor:
Efstratios Mainas, Joseph Meletiadis, Efthymios Neroutsos, Iasonas Kapralos, Maria Siopi, Georgia Valsami, Aristides Dokoumetzidis, George Dimopoulos, Stella Apostolidi, Helen Sambatakou, Olympia Apostolopoulou
Publikováno v:
The Journal of pharmacy and pharmacologyReferences. 72(12)
Objectives To study the population pharmacokinetics of micafungin in critically ill patients, evaluate and optimize dosage regimens. Methods An HPLC–fluorescence bioassay for micafungin was developed, fully validated and applied to a pharmacokineti
Autor:
Georgia Valsami, Iasonas Kapralos, Helen Sambatakou, Efstratios Mainas, Maria Siopi, Efthymios Neroutsos, Olympia Apostolopoulou, Aristides Dokoumetzidis, George Dimopoulos, Stella Apostolidi, Joseph Meletiadis
Publikováno v:
British journal of clinical pharmacologyREFERENCES. 87(3)
Aims The population pharmacokinetics (PK) of anidulafungin in critically ill patients hospitalized in intensive care units (ICUs) was explored with the intention of evaluating and optimizing dosing regimens. Methods A PK study was conducted in a coho
Autor:
David P. Nicolau, Iasonas Kapralos, George Dimopoulos, M.P. Almyroudi, A. Flevari, Olympia Apostolopoulou, Aris Dokoumetzidis
Publikováno v:
International Journal of Antimicrobial Agents. 59:106487
Objectives Tigecycline is commonly used for treating infections caused by multidrug resistant bacteria. However, it is not approved for ventilator associated pneumonia(VAP), as increased mortality has been reported in patients with VAP treated with c